PVX-001: open-source Covid-19 vaccine starts Phase 1 trial
Summary
PVX-001 is an open-source COVID-19 vaccine candidate entering a Phase I trial in Melbourne, driven by an AI-powered design workflow and an RNA-encoded virus-like particle (VLP) platform. The post highlights the manufacture-at-scale approach, fridge-stable lipid nanoparticles, and a commitment to open-source the design and manufacturing data after the trial, signaling a shift toward rapid, collaborative biotech innovation.